Business Wire·Sep 17, 2026, 8:00 AM ET

bioAffinity Technologies Announces Grant of Hong Kong Patent for Company's CyPath® Lung Noninvasive Lung Cancer Diagnostic

bioAffinity Technologies announced that the Hong Kong Intellectual Property Department granted Patent No. HK40048460 for its proprietary CyPath Lung technology.
The granted Hong Kong patent strengthens intellectual property protection alongside a 2025 patent received from China to support entry into the Asian market.
The patent covers a system using defined antibodies & the porphyrin TCPP to label cell populations in sputum, utilizing flow cytometry to detect lung cancer cells.
Asia accounts for nearly two-thirds of global lung cancer cases, with an estimated 1.6 million new diagnoses annually.
CyPath Lung is a noninvasive Laboratory Developed Test (LDT) that uses flow cytometry & artificial intelligence to assess malignancy likelihood in lung nodules detected by low-dose CT scans.
Clinical trial data for high-risk patients showed 92% sensitivity, 87% specificity, 88% accuracy, & 99% negative predictive value for detecting lung cancer in nodules under 20 millimeters.
The technology is marketed as an LDT overseen under CLIA regulations by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies.
The company's global patent estate now includes multiple patents & pending applications in the US, Australia, Canada, China, the EU, Japan, Mexico, & Singapore.